The role of «hunger hormone» in the regulation of eating behavior in patients with Parkinson’s disease

2021 ◽  
Author(s):  
K. A. Tarianyk
Keyword(s):  
Parkinson’S Disease ◽  
Body Mass Index ◽  
Parkinson's Disease ◽  
Body Mass ◽  
Eating Behavior ◽  
Disease Duration ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Clear Correlation ◽  
Group 2

Objective — to evaluate the correlation between ghrelin levels, body mass index and the course of the disease in patients with Parkinson’s disease Methods and subjects. We examined 40 patients with Parkinson’s disease and 20 patients without signs of neurodegenerative disease (control group), who were examined and admitted to the neurological department. Patients were distributed into groups: 1 group — 20 patients with a disease duration of 12.1 ± 2.3 years, group 2 — 20 patients with a disease duration of 7.3 ± 1.6 years, group 3 — control, 20 patients without signs of morbidity. The diagnosis was made according to the criteria of the World Brain Bank of Great Britain. The severity of the disease was determined by the Hen and Yar scale. All patients, after signing the consent agreement, underwent a general clinical, neurological examination with assessment of anthropometric parameters: height, weight, body mass index. Also, patients underwent laboratory determination of serum ghrelin levels using the method of enzyme‑linked immunosorbent assay (ELISA) on the basis of the Research Institute of Genetic, Immunological Basis of Pathology and Pharmacogenetics of the Ukrainian Medical Dental Academy. Results. Studies indicate that in the group of patients with a longer course of the disease (group 1) there was an increase in BMI, which can be interpreted as obesity or overweight, compared with group 2 and control, where the rate was normal. In group 2, where the duration of the disease was shorter, there was a decrease in BMI, accompanied by weight loss of patients. In each group of examined patients there were patients with different forms of the disease, but in the second group patients with akinetic‑rigid form of the disease prevailed, so these patients in neurological status suffered more from stiffness, immobility. Normally, ghrelin level rises in the morning during hunger and decreases after eating. A similar picture was observed in the control group of patients, where the rate of morning ghrelin was elevated. When assessing fasting plasma ghrelin levels in groups of patients, there is a slight decrease in the indicator compared with the control group. Conclusions. There is a clear correlation between the duration of the disease, body mass index and hunger hormone levels in patients with Parkinson’s disease. In patients with the initial stages of the disease there is a decrease in body mass index, which is a prognostically unfavorable sign. Fluctuations in ghrelin levels may be associated with decreased energy intake due to gastrointestinal dysfunction, increased energy expenditure caused by motor manifestations of the disease, or increased glucose metabolism with the use of drugs and changes in the eating behavior of patients.  

Body mass index in Parkinson’s disease: A meta-analysis

2012 ◽  
Vol 18 (3) ◽  
pp. 263-267 ◽  
Author(s):  
Marjolein A. van der Marck ◽  
Heleen C. Dicke ◽  
Ergun Y. Uc ◽  
Zippora H.A. Kentin ◽  
George F. Borm ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Body Mass Index ◽  
Parkinson's Disease ◽  
Body Mass ◽  
Meta Analysis

scholarly journals Osteosarcopenia in chronic pancreatitis

2021 ◽  
Vol 93 (8) ◽  
pp. 869-875
Author(s):  
Irina V. Kozlova ◽  
Anna P. Bykova
Keyword(s):  
Risk Factors ◽  
Body Mass Index ◽  
Chronic Pancreatitis ◽  
Body Mass ◽  
Assessment Tool ◽  
Reproductive Function ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Colon Mucosa ◽  
Traditional Risk Factors

Aim. To determine clinical features and some mechanisms of osteosarcopenia development in patients with chronic pancreatitis (CP). Materials and methods. A casecontrol study was conducted on the basis of the Saratov State Clinical Hospital 5 in 20152018 of patients with CP. In a study of 161 patients with CP included, the control group 30 healthy individuals. Patients were divided into groups according to the etiology of CP: 79 with toxic-metabolic CP, 82 with biliary CP. To determine the risks of low-energy fractures, 154 patients were tested with the Fracture risk assessment tool (FRAX). Along with the standard examination, 30 patients with CP dual-energy X-ray absorptiometry was performed. To assess the state of skeletal muscles, body mass index was determined, hand-held dynamometry was performed, and a set of Short Physical Performance Battery (SPPB) tests was used. Along with the assessment of traditional risk factors for osteosarcopenia gender, age, state of reproductive function in women, body mass index, functional state of the pancreas (pancreas) the quantitative content of interleukins (IL)-2, 6, 8 in in colonic biopsies was analyzed by enzyme-linked immunosorbent assay (ELISA). Results. Bone disorders, according to densitometry, was detected in 70.0% of patients with CP, in 13.3% of the control group. Presarcopenia was detected in 62 (38.5%) patients with CP, sarcopenia in 34 (21.1%), in the control group presarcopenia and sarcopenia were not detected. Sarcopenia was statistically significantly more common in toxic-metabolic CP than in biliary CP (2=11.6; p0.001). Correlations of the lumbar spine T-score and IL-6 (r=-0.29; p=0.03), IL-8 (r=-0.29; p=0.04) were revealed. Correlations between sarcopenia and the concentration of cytokines in the in the colon mucosa in CP were determined (IL-2: r=0.44; p0.001; IL-6: r=0.48; p0.001; IL-8: r=0.42; p0.001). Conclusion. The development of osteopenia and sarcopenia syndromes in CP is interrelated and associated with both traditional risk factors and an increased concentration of cytokines in the in the colon mucosa.

Relationship between changes of body mass index (BMI) and cognitive decline in Parkinson's disease (PD)

2012 ◽  
Vol 55 (1) ◽  
pp. 70-72 ◽  
Author(s):  
Hyun Jung Kim ◽  
Eung Seok Oh ◽  
Ji Hee Lee ◽  
Jung Soo Moon ◽  
Ji Eun Oh ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Body Mass Index ◽  
Parkinson's Disease ◽  
Cognitive Decline ◽  
Body Mass

Body mass index in Parkinson's disease

2005 ◽  
Vol 11 (6) ◽  
pp. 407 ◽  
Author(s):  
Renato P. Munhoz ◽  
Carolina B. Ribas
Keyword(s):  
Parkinson’S Disease ◽  
Body Mass Index ◽  
Parkinson's Disease ◽  
Body Mass

scholarly journals Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study

2015 ◽  
Vol 73 (3) ◽  
pp. 241-245 ◽  
Author(s):  
Vanessa Alatriste-Booth ◽  
Mayela Rodríguez-Violante ◽  
Azyadeh Camacho-Ordoñez ◽  
Amin Cervantes-Arriaga
Keyword(s):  
Parkinson’S Disease ◽  
Body Mass Index ◽  
Parkinson's Disease ◽  
Sleep Disorders ◽  
Body Mass ◽  
Behavior Disorder ◽  
Equivalent Dose ◽  
Movement Behavior ◽  
Single Night ◽  
Hypopnea Syndrome

Objective Sleep disorders in Parkinson’s disease are very common. Polysomnography (PSG) is considered the gold standard for diagnosis. The aim of the present study is to assess the prevalence of nocturnal sleep disorders diagnosed by polysomnography and to determine the associated clinical factors. Method A total of 120 patients with Parkinson’s disease were included. All patients underwent a standardized overnight, single night polysomnography. Results Ninety-four (78.3%) patients had an abnormal PSG. Half of the patients fulfilled criteria for sleep apnea-hypopnea syndrome (SAHS); rapid eye movement behavior disorder (RBD) was present in 37.5%. Characteristics associated with SAHS were age (p = 0.049) and body mass index (p = 0.016). Regarding RBD, age (p < 0.001), left motor onset (p = 0.047) and levodopa equivalent dose (p = 0.002) were the main predictors. Conclusion SAHS and RBD were the most frequent sleep disorders. Higher levodopa equivalent dose and body mass index appear to be risk factors for RBD and SAHS, respectively.

scholarly journals Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease

2021 ◽  
Vol 13 ◽  
Author(s):  
Xu-Ying Li ◽  
Wei Li ◽  
Xin Li ◽  
Xu-Ran Li ◽  
Linjuan Sun ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Duration ◽  
Late Onset ◽  
Area Under The Curve ◽  
Alpha Synuclein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Olfactory Loss ◽  
Potential Biomarker

Serine 129-phosphorylated alpha-synuclein (pS-α-syn) is a major form of α-syn relevant to the pathogenesis of Parkinson's disease (PD), which has been recently detected in red blood cells (RBCs). However, alterations of RBC-derived pS-α-syn (pS-α-syn-RBC) in different subtypes and stages of PD remains to be investigated. In the present study, by using enzyme-linked immunosorbent assay (ELISA) to measure pS-α-syn-RBC, we demonstrated significantly higher levels of pS-α-syn-RBC in PD patients than in healthy controls. pS-α-syn-RBC separated the patients well from the controls, with a sensitivity of 93.39% (95% CI: 90.17–95.81%), a specificity of 93.11% (95% CI: 89.85–95.58%), and an area under the curve (AUC) of 0.96. Considering motor subtypes, the levels of pS-α-syn-RBC were significantly higher in late-onset than young-onset PD (p = 0.013) and in those with postural instability and gait difficulty than with tremor-dominant (TD) phenotype (p = 0.029). In addition, the levels of pS-α-syn-RBC were also different in non-motor subtypes, which were significantly lower in patients with cognitive impairment (p = 0.012) and olfactory loss (p = 0.004) than in those without such symptoms. Moreover, the levels of pS-α-syn-RBC in PD patients were positively correlated with disease duration and Hoehn &amp; Yahr stages (H&amp;Y) (p for trend =0.02 and &lt;0.001) as well as UPDRS III (R2 = 0.031, p = 0.0042) and MoCA scores (R2 = 0.048, p = 0.0004). The results obtained suggest that pS-α-syn-RBC can be used as a potential biomarker for not only separating PD patients from healthy controls but also predicting the subtypes and stages of PD.

scholarly journals Therapeutic effect of TO901317 on 6-OHDA-induced Parkinson rats in vitro and in vivo

2020 ◽  
Author(s):  
Miaomiao Li ◽  
Junqing Yang ◽  
Oumei Cheng ◽  
Zhe Peng ◽  
Yin Luo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Dopamine Neurons ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor 8

Abstract Background: Stem cells from different sources could differentiate into dopamine-producing cells and ameliorate behavioral deficits in Parkinsonian models. Especially, human bone marrow mesenchymal stem cells (hBMSCs) have many advantages without ethical dispute. Liver X receptor s (LXRs) are involved in the maintenance of the normal function of the central nervous system myelin. We have reported the induction of cocktail-induced da phenotypes from adult rat BMSCs by using sonic hedgehog (SHH), fibroblast growth factor 8 (FGF8), basic fibroblast growth factor (bFGF) and TO901317 (agonist of LXRs) with 87.42% of efficiency in 6 days of period of induction. But the previous work did not verify whether the induced cells had the corresponding neural function. Methods: In this study, we demonstrated that TO901317 could promote the differentiation of hBMSCs into dopaminergic neurons. Neuronal markers (Tuj1, Neun and Nestin), dopamine neuron markers (tyrosine hydroxylase, TH), LXRa and LXRb were detected by immunofluorescence. RT-qPCR was used to measure the mRNA expressions of adenosine triphosphate-binding cassette transporter A1 (ABCA1). Western Blotting detected the changes of LXRa, LXRb and TH expression. Results: TO901317 significantly enhanced the differentiation from hBMSCs to DA neurons. Only the LXR+GF group released dopamine by the result of enzyme linked immunosorbent assay (ELISA). Compared with the control group and GF group, the optimal time for differentiation of hBMSCs treated by 0.5mM TO901317 combined with GF was six days. And the maximum induction efficiency was 91.67%. After transplanting induced-cells into Parkinson's disease rats, the symptoms of Parkinson's rats decreased, and the number of dopamine neurons increased in the substantia nigra and striatum. Conclusions: TO901317 promoted differentiation of hBMSCs into dopamine neurons may be related to activation of LXR-ABCA1 signaling pathway. These data suggest that TO901317 may serve as a potential therapeutic methods for Parkinson's disease.

scholarly journals Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson’s disease

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Zhu Liu ◽  
Qingli Fan ◽  
Shizheng Wu ◽  
Yaqi Wan ◽  
Yancheng Lei
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
High Density Lipoprotein ◽  
Predictive Value ◽  
Disease Duration ◽  
Density Lipoprotein ◽  
High Density ◽  
Neutrophil To Lymphocyte Ratio ◽  
Control Group ◽  
Lymphocyte Ratio

Abstract Background The inflammatory response plays essential roles in the pathological process and prognosis of Parkinson’s disease (PD). This research investigated the predictive value of the neutrophil to high-density lipoprotein ratio (NHR), neutrophil to lymphocyte ratio (NLR), and monocyte to high-density lipoprotein ratio (MHR) for PD. Methods Patients with PD (n = 98) were divided into three groups according to disease duration: < 6 years (n = 55), 6–10 years (n = 29) and > 10 years (n = 14). Based on the classification system of Hoehn and Yahr, grades 1 ~ 2.5 were considered early-stage PD (n = 44), and grades 3 ~ 5 were considered advanced-stage PD (n = 54). In addition, healthy subjects (n = 98) matched to the above PD patients in the same period were selected as the control group. Differences in the NHR, NLR, MHR and other indicators among the groups were evaluated. Results Smoking, drinking, the neutrophil count and the NHR and NLR were remarkably greater and hypertension, index of body mass, the lymphocyte count, and the levels of cholesterol in total, triglycerides, lipoprotein cholesterol with low density and uric acid were sharply lower in the PD group compared with in the control group. Analysis of multifactor logistic regression indicated that the NHR (odds ratio (adjusted OR) = 1.576, 95% CI: 1.053 ~ 2.358, P = 0.027) and NLR (adjusted OR = 1.734, 95% CI: 1.046 ~ 2.876, P = 0.033) were factors of risk for PD, while the MHR was not significantly correlated with PD. The areas under the receiver operating characteristic (ROC) curve (AUCs) for the prediction of PD by the NHR and NLR were 0.654 (95% CI: 0.583 ~ 0.721, P = 0.0001) and 0.69 (95% CI: 0.62 ~ 0.754, P < 0.0001), respectively, and the optimal cutoff values were 1.848 × 109/mmol and 2.62 × 109/mmol. Spearman’s correlation analysis indicated that the NHR was correlated with the disease duration significantly negatively and that the MHR was positively correlated with disease severity. Conclusions In summary, the NHR not only has strong predictive value for PD but is also closely related to disease duration. The NHR may be a better prediction for the long-period clinical results in PD patients than the MHR and NLR. Trial registration Clinical medical reserach center project of Qinghai Province (2017-SF-L1).

Sign in / Sign up

Export Citation Format

Share Document